ASCO 2022 | Combination approaches for the treatment of MF patients who progress after JAK inhibitor therapy
Naveen Pemmaraju
• 5 Jun 2022
Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, highlights some combination approaches being investigated for the treatment of myelofibrosis (MF) patients who progress after JAK inhibitor therapy. This field is rapidly progressing, and some approaches include combining another drug with a JAK inhibitor, novel agents targeting other pathways, and targeting the anemia of myelofibrosis. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
